Antigen release resulting from the death of tumour cells induced by chemotherapies and targeted therapies can augment the antitumour responses induced by immune checkpoint blockade (ICB). However, tumours responding to ICB therapies often become resistan
As a very promising immunotherapy, PD-1/PD-L1 blockade has revolutionized the treatment of a variety of tumor types, resulting in significant clinical efficacy and lasting responses. However, these therapies do not work for a large proportion of patients initially, which is called primary resistanc...
P3.02-050 Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell LinesIntroduction Cancer cells can achieve immune evasion by expressing the programmed death receptor 1 ligand (PD-L1) on the cell surface. Blockade of the receptor (PD-1) can avert this ...
Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC), occurring in a majority of initial responders. Patients with AR may have unique properties of persistent antitumor immunity that could be...
et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526, 263–267 (2015). Article CAS PubMed PubMed Central Google Scholar Heist, R. S. et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J. Thorac. Oncol. 11, 1242–1245 ...
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer Sequential use of EGFR-TKIs promotes EGFR treatment resistance in EGFR-mutant NSCLC.Dual EGFR blockade offers a unique treatment strategy in EGFR-resistant... F Ciardiello,FR Hirsch,R Pirker,... - 《Ca...
[44]. Knock-out of β2M in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo,proving its role in the resistance to ICIs [40]. Tran et al. [45] described the direct loss of the chromosome 6 haplotype encoding the HLA-C*08:02 in a patient with...
Of interest, PD-1/PD-L1 blockade has a tight link with chemotherapy efficacy. The positive responses to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC [11] suggest that sequential schemes involving PD-1/PD-L1 inhibitors followed by chemotherapy can ...
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors JAMA Oncol., 4 (2018), pp. 1237-1244 Google Scholar 18 T. Network, Cancer Genome Atlas Research Network Comprehensive molecular profiling of lung adenocarcinoma Nature, 511 (2014), pp. 543-550...
In the last years, multiple mechanisms of resistance have been identified; however, after progressing on osimertinib, treatment options remain bleak. In this review, we cover the most frequent alterations and potential therapeutic strategies to overcome them. Keywords: osimertinib; NSCLC; EGFR; ...